Germany: Leaked Pricing Measures Could Have ‘Drastic’ Consequences For Orphans
'Dangerous’ new measures outlined in a leaked bill would be a disaster for orphan drugs and lead to companies opting out of the German market, says one industry executive.
You may also be interested in...
BMS Decides Against Opdualag Launch In Germany
BMS says that recent reforms to the benefit assessment system have led to the “deterioration” of the German market.
New German Law Tightens Volume Agreements & Links Prices To Wastage
New cost saving measures in Germany include mandatory volume agreements that will prompt companies to take more account of the size of the populations targeted by their products. Meanwhile, a new link between product wastage and prices should encourage some companies to think about their pack sizes.
New German Law Gives Payers More Power Over Drug Pricing
A new law aimed at limiting drug spending in Germany will mean that only companies with new products that offer high levels of added benefit will have full flexibility to negotiate prices.